Zydus Lifesciences on Monday said it has received approval from US health regulator USFDA to market a generic antifungal medication to treat dandruff, fungal infections, and other skin conditions.
The company has received final approval from the US Food and Drug Administration to manufacture Ketoconazole Shampoo, 2 pc, it said in a statement.
Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.
The product will be produced at the Zydus Group's topical manufacturing site at Changodar, Ahmedabad.
ADVERTISEMENT
As per IQVIA MAT January 2025 data, Ketoconazole shampoo had annual sales of $68.89 mn in the US.
Shares of Zydus Lifesciences were trading 0.22% up at Rs 903.10 apiece on BSE.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Alembic Pharma Gets USFDA Nod For Generic Drug To Treat Depression, Anxiety
Sep 25, 2025
Good Hair Days Incoming? GST 2.0 May Be Making Personal Care Items Cheaper
Sep 21, 2025
From Dove To Vicks: P&G, Emami, HUL Slash Prices To Extend GST Benefits — Check New Rate
Sep 18, 2025
.jpeg?rect=0%2C0%2C3500%2C1969&w=320)
HUL Slashes Product Prices Ahead Of GST Rollout
Sep 13, 2025
POPULAR
1
Trump Says US Tariffs On Heavy Truck Imports To Begin Nov. 1
2
Army Integrates More AI Technologies To Improve Combat Capabilities
3
Oil Prices Rise In Relief Rally As OPEC+ Agrees Modest Production Hike
4
US Stocks Rise To Record As AMD Deal Powers AI Bets: Markets Wrap
5
